Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Carboplatin and Gemcitabine in Metastatic TNBC
NCT02755272Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- May 2016
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Fox Chase Cancer Center. Started May 2016; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02755272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02755272.